Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.
Hear the results of a trial to determine the feasibility of switching patients with multifocal motor neuropathy on intravenous to subcutaneous immunoglobulin.
Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.
Hear the results of a trial to determine the feasibility of switching patients with multifocal motor neuropathy on intravenous to subcutaneous immunoglobulin.